drugset / Trial / NCT05983107
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients and to explore the efficacy and safety of Everolimus combined with endocrine therapy in patients with PI3KCA Mutant HR+/HER2- advanced breast cancer.
Timeline
- Start
- 2023-07-20
- Primary completion
- 2026-07-15
- Completion
- 2027-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | — | — |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Tamoxifen | Small molecule | — | — |